OncoTherapy Science, Inc.
4564.T · JPX
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | ¥8,285 | ¥8,618 | ¥7,601 | ¥6,793 |
| - Cash | ¥1,675 | ¥1,228 | ¥834 | ¥945 |
| + Debt | ¥23 | ¥37 | ¥51 | ¥65 |
| Enterprise Value | ¥6,632 | ¥7,427 | ¥6,818 | ¥5,913 |
| Revenue | ¥230 | ¥201 | ¥187 | ¥338 |
| % Growth | 14.4% | 7.9% | -44.7% | – |
| Gross Profit | ¥33 | -¥4 | ¥11 | ¥40 |
| % Margin | 14.1% | -1.8% | 5.9% | 12% |
| EBITDA | -¥240 | -¥313 | -¥115 | -¥171 |
| % Margin | -104.1% | -155.6% | -61.7% | -50.5% |
| Net Income | -¥241 | -¥314 | -¥98 | -¥172 |
| % Margin | -104.5% | -156% | -52.5% | -50.9% |
| EPS Diluted | -0.76 | -1.13 | -0.36 | -0.63 |
| % Growth | 32.7% | -213.9% | 42.9% | – |
| Operating Cash Flow | – | ¥0 | ¥0 | ¥0 |
| Capital Expenditures | – | ¥0 | ¥0 | ¥0 |
| Free Cash Flow | – | ¥0 | ¥0 | ¥0 |